Low Dose Naltrexone as it is known in the United States, or Lodonal as it is known internationally, has its origins in the FDA approved 50mg Naltrexone. Originally used to treat opiate dependences, the Immune Therapeutics patented treatments, which cover a wide range of indications, is currently used as an immune modulator.
OGF/MENK has been shown to halt the growth of the cells and is thought to allow immunological mechanisms (e.g. macrophages, natural killer cells) to accomplish the task of destroying the cancerous cells.
ORLANDO, Fla., March 17, 2017 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal™, its proprietary formulation of lower-dose naltrexone, announced today that the Dominican Republic Ministry of Public Health has granted Immune’s request to export Lodonal to Kenya.
– Company Redeems Nearly All Outstanding Convertible Debentures
– Replaces Nearly $650,000 of Long-Term Debt with Financing on Significantly Better Terms from a Strategic Long-Term Institutional Investor
– Company’s Latest Strategic Financial and Operational Initiatives Prepares Immune for Commercialization of its Blockbuster Drug Lodonal™
– Company On-Track Towards Achieving Cash Flow Positive Status in First Half 2017 and Profitability by Fiscal Year-End
– Following Launch of Lodonal, Management to Provide Greater Detail Over Pipeline of its Various Drugs in the Approval Process both with the FDA and Internationally
– Management to Update Shareholders on Better than Expected Progress Shortly
Immune Therapeutics, Inc. (OTCQB: IMUN), a clinical-stage pharmaceutical company developing novel, non-toxic affordable therapies to treat immuno-inflammatory diseases and cancer in emerging markets, today announced that it has signed a Memorandum of Understanding (“MOU”) for distribution of its patented Lodonal™ in Kenya.